Engineering strategies to overcome the current roadblocks in CAR T cell therapy
S Rafiq, CS Hackett, RJ Brentjens - Nature reviews Clinical oncology, 2020 - nature.com
T cells genetically engineered to express chimeric antigen receptors (CARs) have proven—
and impressive—therapeutic activity in patients with certain subtypes of B cell leukaemia or …
and impressive—therapeutic activity in patients with certain subtypes of B cell leukaemia or …
[HTML][HTML] Engineering CAR-T cells for next-generation cancer therapy
M Hong, JD Clubb, YY Chen - Cancer cell, 2020 - cell.com
T cells engineered to express chimeric antigen receptors (CARs) with tumor specificity have
shown remarkable success in treating patients with hematologic malignancies and …
shown remarkable success in treating patients with hematologic malignancies and …
Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors
E Liu, D Marin, P Banerjee… - … England Journal of …, 2020 - Mass Medical Soc
Background Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy has shown
remarkable clinical efficacy in B-cell cancers. However, CAR T cells can induce substantial …
remarkable clinical efficacy in B-cell cancers. However, CAR T cells can induce substantial …
Targeting cytokine and chemokine signaling pathways for cancer therapy
Cytokines are critical in regulating immune responses and cellular behavior, playing dual
roles in both normal physiology and the pathology of diseases such as cancer. These …
roles in both normal physiology and the pathology of diseases such as cancer. These …
CAR-T cell therapy in hematological malignancies: current opportunities and challenges
X Zhang, L Zhu, H Zhang, S Chen, Y **ao - Frontiers in immunology, 2022 - frontiersin.org
Chimeric antigen receptor T (CAR-T) cell therapy represents a major breakthrough in cancer
treatment, and it has achieved unprecedented success in hematological malignancies …
treatment, and it has achieved unprecedented success in hematological malignancies …
Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trial
There is a pressing need for allogeneic chimeric antigen receptor (CAR)-immune cell
therapies that are safe, effective and affordable. We conducted a phase 1/2 trial of cord …
therapies that are safe, effective and affordable. We conducted a phase 1/2 trial of cord …
Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management
JN Brudno, JN Kochenderfer - Blood reviews, 2019 - Elsevier
Chimeric antigen receptor (CAR) T-cell therapy is an effective new treatment for hematologic
malignancies. Two CAR T-cell products are now approved for clinical use by the US FDA …
malignancies. Two CAR T-cell products are now approved for clinical use by the US FDA …
The future of cancer treatment: immunomodulation, CARs and combination immunotherapy
DN Khalil, EL Smith, RJ Brentjens… - Nature reviews Clinical …, 2016 - nature.com
In the past decade, advances in the use of monoclonal antibodies (mAbs) and adoptive
cellular therapy to treat cancer by modulating the immune response have led to …
cellular therapy to treat cancer by modulating the immune response have led to …
Therapeutic T cell engineering
M Sadelain, I Rivière, S Riddell - Nature, 2017 - nature.com
Genetically engineered T cells are powerful new medicines, offering hope for curative
responses in patients with cancer. Chimaeric antigen receptors (CARs) are a class of …
responses in patients with cancer. Chimaeric antigen receptors (CARs) are a class of …
Loss of metabolic fitness drives tumor resistance after CAR-NK cell therapy and can be overcome by cytokine engineering
Chimeric antigen receptor (CAR) engineering of natural killer (NK) cells is promising, with
early-phase clinical studies showing encouraging responses. However, the transcriptional …
early-phase clinical studies showing encouraging responses. However, the transcriptional …